July 12 - New epilepsy data sets Zogenix up for showdown with GW

BioPharma Dive's Top News

Daily edition | July 12, 2018

BROUGHT TO YOU BY — ZS

Unlock the Secret of Patient Centricity

Watch this video series to learn how R&D leaders can prepare their organization for a patient-centric future. Click here

New epilepsy data sets Zogenix up for showdown with GW

More late-stage data showed patients with a rare form of epilepsy had greater reductions in monthly seizures when taking ZX008 compared to placebo.

Dermavant finds 'cornerstone' drug in GSK's pipeline

The British pharma will out-license tapinarof, in testing for psoriasis and atopic dermatitis, to Dermavant for nearly $200 million.

New FDA guidance aimed at advancing gene therapy

A suite of new and updated agency documents brings the prospect of more gene therapy approvals closer.

Rethinking trial protocols to advance patient-centricity

Trial designers seek insight into patient burden to help plan more effective, patient-first trials.

Enzyvant initiates value-based pricing talks ahead of filing

The "Vant" hopes to set up a deal with payers before a potential approval of its experimental one-time therapy for an extremely rare pediatric disease.

BioCryst nixes merger, sending Idera stock down

Both companies are trying to find a path forward after plans to join were dropped.

Dova downgraded as high price tag threatens to slow new drug's pickup

The biotech believes Doptelet could tap into a multibillion dollar market, but some analysts question whether that could happen anytime soon.

At Clinipace, It's Personal

At Clinipace, a global, full-service CRO, our approach to clinical research is personal. We overcome difficult challenges across major therapeutic areas with personalized services and solutions, local regulatory expertise and therapeutic leadership. Learn more about our CHALLENGE ACCEPTED approach.